We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers includ... Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Show more
Bain Capital (NYSE:BCSF), PowerSchool Holdings (NYSE:PWSC) – Bain Capital is in talks to purchase PowerSchool, an educational software provider, in a private deal that could value the...
Pfizer Inc. (NYSE: PFE) today announced that Andrew Baum, M.D., will join the company as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s...
Shares of CVS Health (NYSE:CVS) are moving sharply lower in pre-market trading after the drugstore chain and pharmacy benefit manager reported weaker than expected first quarter results and cut...
Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities First-Quarter 2024 Revenues of $14.9 Billion Expected Decline in Comirnaty(1) and...
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this...
More than 50 abstracts, including 11 oral presentations, span Pfizer’s robust portfolio of approved and pipeline therapies across its key tumor areas and core scientific modalities New five-year...
BHP Group (NYSE:BHP) – Anglo American has rejected BHP’s acquisition proposal of $38.88 billion, stating it significantly undervalues the company and its future prospects. The offer...
A one-time dose of BEQVEZ has reduced bleeds post-treatment compared to standard of care with a median of zero bleeds (range 0 to 19) after up to three years of follow-up, providing sustained...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.12 | 0.430725053841 | 27.86 | 28.49 | 27.32 | 54523553 | 28.00796769 | CS |
4 | 1.73 | 6.59047619048 | 26.25 | 28.49 | 25.2 | 46183246 | 26.70071623 | CS |
12 | 0.42 | 1.52394775036 | 27.56 | 28.69 | 25.2 | 43490687 | 27.02376413 | CS |
26 | -1.77 | -5.94957983193 | 29.75 | 30.75 | 25.2 | 44538437 | 27.65314001 | CS |
52 | -10.72 | -27.7002583979 | 38.7 | 40.365 | 25.2 | 35721384 | 30.60144764 | CS |
156 | -11.85 | -29.7514436355 | 39.83 | 61.71 | 25.2 | 29779151 | 40.9373728 | CS |
260 | -12.65 | -31.1346295841 | 40.63 | 61.71 | 25.2 | 29446697 | 39.39660826 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions